Drugs / VENANPRUBART
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04975295 | Jul 2021 → Nov 2022 | psoriasis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03933943 | May 2019 → Feb 2021 | systemic lupus erythematosus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03695198 | Oct 2018 → Aug 2019 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05781451 | Jan 2025 → Jan 2027 | Sjogren syndrome | Stanford University | Withdrawn | No outcome recorded |
| Phase 2 | NCT05123586 | Mar 2022 → Dec 2023 | systemic lupus erythematosus | Eli Lilly and Company | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VENANPRUBART | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314624 ↗ |
| Known as | LY3361237 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05123586 ↗ |
| Modality | Monoclonal antibody | — CHEMBL5314624 ↗ |
| Route | Subcutaneous | “LY3361237 administered SC” NCT03695198 ↗ |